<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709771</url>
  </required_header>
  <id_info>
    <org_study_id>181796</org_study_id>
    <nct_id>NCT03709771</nct_id>
  </id_info>
  <brief_title>Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease</brief_title>
  <official_title>Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the effect of vascular endothelial growth factor&#xD;
      tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination&#xD;
      treatment on blood pressure and blood vessel function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean blood pressure</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Mean 24 hour blood pressure from ambulatory 24 hour recording</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of post-treatment to pre-treatment change in digital pulse amplitude</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>Digital pulse amplitude will be measured using peripheral artery tonometry</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Hypertension</condition>
  <condition>Melanoma</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>VEGF inhibitor alone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Checkpoint Inhibitor (ICI) alone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination (VEGF inhibitor + ICI, or combination of ICI)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ambulatory Blood Pressure Measurement</intervention_name>
    <description>Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.&#xD;
Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure.</description>
    <arm_group_label>Combination (VEGF inhibitor + ICI, or combination of ICI)</arm_group_label>
    <arm_group_label>Immune Checkpoint Inhibitor (ICI) alone</arm_group_label>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_label>VEGF inhibitor alone</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with cancer that will be receiving VEGF inhibitor, ICI, or combination (VEGF&#xD;
        inhibitor plus ICI or combination ICI treatment), or not receiving any treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 40 - 75 years old&#xD;
&#xD;
          -  Diagnosis of cancer&#xD;
&#xD;
          -  Receiving VEGF inhibitor, ICI, or combination (VEGF inhibitor + ICI or combination&#xD;
             ICI) treatment, or not receiving any treatment.&#xD;
&#xD;
          -  Normal blood pressure or blood pressure treated to &lt; 140/90 mm Hg with â‰¤2&#xD;
             antihypertensive medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of peripheral artery disease&#xD;
&#xD;
          -  History of a heart attack within 1 year&#xD;
&#xD;
          -  History of a stroke within 1 year&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Women who are nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Beckman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Shardelow, BS</last_name>
    <phone>615-875-8949</phone>
    <email>emily.m.shardelow@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Shardelow, BS</last_name>
    </contact>
    <investigator>
      <last_name>Joshua Beckman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Joshua Beckman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by an independent review committee (&quot;learned intermediary&quot;) identified for this purpose.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

